Morphological changes in connective tissue diseases
DOI:
https://doi.org/10.5281/zenodo.1467773Keywords:
morphological changes, connective tissue diseases, , multi-systemic, autoimmune diseaseAbstract
Introduction: Connective tissue diseases are a health concern for healthcare institutions in any country, not only because of the symptoms they present, which is a reason for frequent medical attention, but also because of the need for care, high health costs and the great negative effects on the quality of life generated in the lives of people who suffer from them.
Objective: To reflect about some connective tissue diseases and their structural and morphological complications.
Development: During the analysis of the consulted literature, we could verify the existence of a group of systemic autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, inflammatory myopathies, antiphospholipid syndrome, Sjögren's syndrome and systemic necrotizing vasculitis, which has drawn the specialists' attention.
Conclusions: Most of these conditions develop with pain, discomfort and limitations to perform activities of daily life, a reason why patients often feel distressed, particularly because these are diseases that can cause irreversible damage with a not always favorable prognosis and whose response to specific treatment is not always satisfactory, which accentuates the discomfort and symptoms in general and gives rise to spiritual anguish and suffering in the patient and their relatives.
Downloads
References
López Mantecón AM, Machado Vázquez LI, Hernández Quintero O, Arvelo Figueredo M, González Hernández C. Exploración del conocimiento sobre cuidados paliativos en el Centro de Reumatología. Revista Cubana de Reumatología, [Internet]. 2014[citado 14 de abril de 2018]; 16(1), 5-14. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962014000100002&lng=es&tlng=es
López Mantecón AM. Cuidados paliativos. Una necesidad en la atención reumatológica. Rev. Cub Reumatología [Internet]. 2013 [citado 14 de abril de 2018]; 15(1), 25-29. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962013000100005&lng=es&tlng=es.
Proaño López NE, Arévalo Ordóñez IM. Elementos que reumatólogos y dermatólogos deberían conocer sobre el lupus eritematoso sistémico. Rev Cubana de Reumatol [Internet]. 2016 [citado 7 Jun 2017];18(2). Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/495
López Rodríguez I, Anchia Guerra N, Crespo Domínguez F, Wainshtok Tomás DM, Reyes Rodríguez M. Fenómeno de Raynaud como manifestación inicial de lupus eritematoso sistémico. Presentación de un caso. Rev Cuba Reumatol [Internet]. 2017 Dic [citado 2018 Abr 11] ; 19(3): 143-149. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962017000300007&lng=es
Méndez Flores S, Orozco Topete R, Bermudez Bermejo P, Hernández Molina G. Lupus eritematoso cutáneo. Rev MedInstMex Seguro Soc [Internet]. 2015 [citado 11 de abril de 2018]; 53(6):764-72. Disponible en:http://www.medigraphic.com/pdfs/imss/im-2015/im156q.pdf
Tapia Casa DB, Sanjuanelo C. Manifestaciones clínicas atípicas no dermatológicas más frecuentes de lupus eritematoso sistémico. Tesis. 2014 [citado 11 de abril de 2018] Universidad de Ciencias Aplicadas, Colombia. Disponible en: http://repository.udca.edu.co:8080/jspui/handle/11158/843
Crow MK. Lupus eritematoso sistémico. En: Goldman Cecil. Tratado de Medicina Interna. 25. pp. 1769-77. Madrid: Ed. Elsevier; 2017.
Porcel Chacón R, Tapia Ceballos L, Díaz Cabrera R, Gutiérrez Perandones MT .Lupus eritematoso neonatal: revisión de casos en los últimos 5 años. Rev Colomb Reumatología [Internet]. 2014[citado 11 de abril de 2018]; 10(3): 170-3. Disponible en: https://www.sciencedirect.com/science/article/pii/S1699258X13002143
Darío Aguirre H, Posada López AF, Aponte Monsalve JE, EstupiñánMF. Lupus eritematoso sistémico en el anciano: una presentación atípica de una enfermedad común.Rev Colomb Reumatología [Internet]. 2014 [citado 11 de abril de 2018];.21 (2),104-8. DOI: 10.1016/S0121-8123(14)70156-2
Estrada Vidal J, Pasalodos N, Pila Pérez R, Ramírez Rodríguez L, Gallardo Roca L. Tratamiento de la nefritis lúpica grado IV con bolos de ciclofosfamida. Archivo Médico de Camagüey [Internet]. 2015 [citado 2018 Abr 11];8(5):[aprox. 0 p.]. Disponible en: http://revistaamc.sld.cu/index.php/amc/article/view/3057
Amezcua-Guerra LM, Hofmann F, Vargas A et al. Joint involvement in primary Sjögren’s syndrome: an ultrasound “target area approach to arthritis”. Biomed Res Int. [Internet].2013[citado 2018 Abr 13]: 640-65.Disponible en:doi: 10.1155/2013/640265
Juarez M, Toms TE, de Pablo P et al. Cardiovascular riskfactors in women with primary Sjögren’ssyndrome: United Kingdom primary Sjögren’ssyndrome registryresults. Arthritis Care Res [Internet].2014[citado 2018 Abr 14]; 66: 757-64. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/acr.22227
Arellano Aguilar G, Magaña Reyes J, Gutiérrez Velazco JL, Domínguez Carrillo LG.Síndrome de Sjögren. ACT MÉD GRUPo ÁNGELES [Internet].2016 [citado 2018 Abr 13]; 14 (2). Disponible en: www.medigraphic.com/pdfs/actmed/am-2016/am162f.pd
Rasmussen A, Kelly JA, Ice J. Characterization of early and progressiveautoimmunity in Sjögren’ssyndrome: thein complete Sjogren’ssyndrome model. Program and abstracts from the 13th International Symposiumon Sjogren’s Syndrome; Bergen, Norway. Abstract S2.10; 2015.
Ramos Casals M, Anaya JM, García Carrasco M. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52patients. Medicine [Internet]. 2004[citado 2018 Abr 13]; 83(2):96-106. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/15028963
Roguedas AM, Misery L, Sassolas B. Cutaneousmanifestations of primary Sjögren’s syndrome are underestimated. Clin Exp Rheumatol. [Internet]. 2004[citado 2018 Abr 13];22(5):632-36. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/15485020
Guellec D, Cornec-Le Gall E, Groh M et al. ANCA-associated vasculitis in patients with primary Sjögren’ssyndrome: detailed analysis of 7 new cases and systematic literature review. Rev Autoimmun [Internet]. 2015[citado 2018 Abr 13]; 14 (8):742-750. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25916811
Dobloug GC, Antal EA, Sveberg L, Garen T, Bitter H, Stjärne J, Grøvle L, Gran JT, Molberg O. High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study. Eur J Neurol [Internet]. 2015[citado 2018 Abr 13]; 22 (4): 672. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25530508
Bartoloni E, Baldini C, Schillaci G, Quartuccio L, Priori R, Carubbi F, Bini V, Alunno A. Cardiovascular diseaseriskburden in primary Sjögren’s syndrome: results of a population-based multicentre cohort study. J Intern Med[Internet].2015 [citado 2018 Abr 13] 278: 185-192. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25582881
Hatron PY(1), Tillie-Leblond I, Launay D, Hachulla E, Fauchais AL, Wallaert B.. Pulmonarymanifestations of Sjögren’ssyndrome. PresseMed [Internet]. 2011[citado 2018 Abr 13];40:49-64. Disponible en: http://www.err.ersjournals.com/content/25/140/110
Saldarriaga Rivera LM, Ventura Ríos L, Hernández Díaz C, Pineda Villaseñor C. Evaluación Ecográfica de la Glándula Salival: Utilidad y Diagnóstico en el síndrome de Sjögren. Rev Cub de Reumatología [Internet]. 2015[citado 2018 Abr 13]; XVII, (2): 178-81. Disponible en: http://www.revreumatologia.sld.cu/
Vissink A, Bootsma H, Spijkervet FK, Hu S, Wong DT, Kallenberg CG. Current and futurechallenges in primary Sjogren’ssyndrome. CurrPharmBiotechnol. [Internet]. 2012[citado 2018 Abr 13]; 13 (10): 2026-45. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22208656
Afzelius P, Fallentin EM, Larsen S et al. Pancreaticfunction and morphology in Sjögren’ssyndrome. Scand J Gastroenterol [Internet]. 2010[citado 2018 Abr 13]; 45:752-58. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/20334476
Lee KL, Chen MY, Yeh JH et al. Lower urinary tract symptoms in female patients with rheumatoid arthritis. Scand J Rheumatol[Internet]. 2006[citado 2018 Abr 13]; 35:96-101. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16641041
Menéndez A, Gómez J, Escanlar E et al. Clinicalassociations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: diagnosticutility of theirseparatedetection. Autoimmunity [Internet].2013[citado 2018 Abr 14]; 46 (1): 32-39.Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23039326
Akpek EK, Mathews P, Hahn S et al. Ocular and systemicmorbidity in a longitudinal cohort of Sjögren’ssyndrome. Ophthalmology [Internet]. 2015 [citado 2018 Abr 14]; 122(1):56-6. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25178806
Becerra UR, Pachuca GD, Alva LL, Menéndez ZS et al. Imagen del síndrome de Sjögren en las glándulas salivales. Rev Invest Med Sur Mex [Internet].2014 [citado 2018 Abr 14]; 21:31-35. Disponible en: https://www.medicasur.org.mx/pdf-revista/RMS141-CP02-PROTEGIDO.pdf
Brito-Zerón P, Akasbi M, Bosch X. Classification and characterisation of peripheralneuropathies in 102 patientswithprimarySjögren’ssyndrome. ClinExpRheumatol[Internet].2013[citado 2018 Abr 14]; 31(1):103-10. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23020902
Klein-Weigel P, Opitz C, Riemekast G. Systemic sclerosis – a systematic overview. Part 1 – Disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. Vasa [Internet].2011 [citado 2018 Abr 14]; 40(1):6-19. Disponible en: https://www.europepmc.org/abstract/MED/21283969
Unanue L, González M, Gardeazabal J. Esclerodermia (esclerosis sistémica). Piel [Internet]. 2010[citado 2018 Abr 14];25 (5): 252-66. Disponible en: https://vdocuments.site/documents/esclerodermia-5874a02fc9526.html
Gómez M. Videocapilaroscopiaperiungueal. Su relevancia en el diagnóstico muy temprano de la esclerosis sistémica. Rev ArgReumatol[Internet]. 2013[citado 2018 Abr 14];24(2):22-25. Disponible en:http://www.revistasar.org.ar/revistas/2013/numero_2/art_3.pdf
Koenig M, Joyal F, Marvin J. Autoantibodies and MicrovascularDamage are independentpredictivefactorsfortheprogression of RaynaudsPhenomenon to SystemicSclerosis. Arthritis&rheumatism[Internet].2008[citado 2018 Abr 14]; 58(12): 3902-12. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/19035499
Avouac J, Fransen J, Walker UA. Preliminarycriteriafortheveryearly diagnosis of systemicsclerosis: results of a Delphi consensusstudyfrom EULAR SCLERODERMA TRIALS AND RESEARCH GROUS. Ann RheumDis[Internet]. 2011 [citado 2018 Abr 14]; 70(3):476-81. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/2108152
Alonso Rodríguez Criollo J, Jaramillo Arroyave D. Fenómeno de Raynaud Rev. Fac. Med. [Internet]. 2014 [citado 15 abril 2018]; 62(3):455-64. Disponible en: http://dx.doi.org/10.15446/revfacmed.v62n3.38934
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
